BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

BioNTech advances oncology pipeline with new trials for BNT327/PM8002 and mRNA immunotherapies targeting various cancers. Quiver AI Summary. BioNTech SE is advancing its oncology strategy with ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

BioNTech stock, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained ...

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur ...

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...